The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | Improving access to systemic therapy in advanced lung cancer care
Lauren Dixon, MBChB, MRes, MRCS, London School of Hygiene & Tropical Medicine, London, UK, discusses the key findings from the State of the Nation report by the National Lung Cancer Audit, highlighting the need to improve access to systemic anti-cancer therapy (SACT) for patients with advanced stage non-small cell lung cancer and good performance status. The report reveals inadequate proportions of eligible patients receiving SACT and excessively long waiting times, emphasizing the importance of addressing these issues to achieve equitable access to SACT in advanced disease. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so one really important finding from the State of the Nation report this year and in previous years is that we’re not having the proportion of patients with advanced stage non-small cell lung cancer and good performance status receiving Systemic Anti-Cancer Therapy (SACT). And we’re also seeing that the waiting times to receive Systemic Anti-Cancer Therapy (SACT) are too long...
Yes, so one really important finding from the State of the Nation report this year and in previous years is that we’re not having the proportion of patients with advanced stage non-small cell lung cancer and good performance status receiving Systemic Anti-Cancer Therapy (SACT). And we’re also seeing that the waiting times to receive Systemic Anti-Cancer Therapy (SACT) are too long. So there’s definitely some work that needs to be done in this area to increase equitable access to Systemic Anti-Cancer Therapy (SACT) in advanced disease. One of the things that the audit is doing is looking at variation. So looking at access to that treatment rates in lots of different places to try to share best practice and also identify opportunities to improve rates of Systemic Anti-Cancer Therapy (SACT) in certain areas.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
